X4 Pharmaceuticals restructuring to advance treatments, reduce spending, extend cash runway.

From GlobeNewswire: 2025-02-06 07:35:00

X4 Pharmaceuticals is focusing on advancing mavorixafor to treat chronic neutropenia and optimizing promotion of XOLREMDI for WHIM syndrome. The company is restructuring, including reducing headcount by 30% and streamlining spending to support clinical development. These changes are expected to decrease annual spending by $30-35 million and extend cash runway into the first half of 2026. X4 is committed to maximizing the global market opportunity for mavorixafor and supporting the immunodeficiency community. The restructuring is aimed at improving operational efficiency and capital efficiency to benefit more patients worldwide.



Read more at GlobeNewswire: X4 Pharmaceuticals Announces Strategic Restructuring to